Again: Hydroxychloroquine Does Not Improve Outcomes for COVID-19 Patients


Health Editor’s Note: Trump has publicly toted ‘cures and preventions’ for COVID-19. One  of these fake cures and one that he admitted to be taking, has continued to be from time to time generally recommended for treatment quality, by anyone who is writing non-peer reviewed medical articles. 

 We have known for weeks that chloroquine and hydroychloroquine do not help patients with COVID-19, but are more likely to harm them by changing the electrical activity of the heart in a bad way. You will continue to see articles written by those who have no real medical knowledge about how we are missing the boat if we do not use these drugs for treatments.  This particular study is quite easy to understand and has all the parts needed to qualify this as a legitimate study.  Can we please stop any further strolling down this hydroxychloroquine/chloroquine dead end alley?….Carol

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

New England Journal of Medicine

  • Alexandre B. Cavalcanti, M.D., Ph.D.,
  • Fernando G. Zampieri, M.D., Ph.D.,
  • Regis G. Rosa, M.D., Ph.D.,
  • Luciano C.P. Azevedo, M.D., Ph.D.,
  • Viviane C. Veiga, M.D., Ph.D.,
  • Alvaro Avezum, M.D., Ph.D.,
  • Lucas P. Damiani, M.Sc.,
  • Aline Marcadenti, Ph.D.,
  • Letícia Kawano-Dourado, M.D., Ph.D.,
  • Thiago Lisboa, M.D., Ph.D.,
  • Debora L. M. Junqueira, M.D.,
  • Pedro G.M. de Barros e Silva, M.D., Ph.D.,
  •  for the Coalition Covid-19 Brazil I Investigators*


Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.


We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed.


A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P=1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P=1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent.

Read More:


We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.